Generic Medicine Info
Indications and Dosage
Short-term management of anxiety, Insomnia
Adult: Up to 3 mg daily in divided doses or as a single dose at night.
Acute narrow-angle glaucoma; myasthenia gravis; resp depression; coma; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment. Chronic psychosis. Phobic or obsessional states; may precipitate suicide or aggressive behavior, not to be used alone to treat depression or anxiety associated with depression. Porphyria. Pregnancy and lactation. Neonates.
Special Precautions
Chronic pulmonary insufficiency, muscle weakness, impaired liver or kidney function, or in patients with history of alcohol or drug addiction. Elderly or debilitated patients. May affect performance of skilled tasks. Patients with personality disorders or organic brain changes. Hypotension occasionally occur with high dosage. Dependence.
Adverse Reactions
Drowsiness, sedation, muscle weakness and ataxia. Less frequently, vertigo, headache, confusion, depression, slurred speech or dysarthria, changes in libido, tremor, visual disturbances, urinary retention or incontinence, GI disturbances, changes in salivation and amnesia.
Drug Interactions
Enhanced sedation or respiratory and CV depression with drugs with CNS depressant properties e.g., antidepressants, antihistamines, antipsychotics, general anaesthetics, other hypnotics or sedatives, opioid analgesics and cisapride. Calcium-channel blockers; clonidine; diazoxide; disulfiram; clozapine; diuretics; moxonidine; nabitone; nitrates; cimetidine, esomeprazole and omeprazole; muscle relaxants; dopaminergics; lofexidine; hydralazine, minoxidil and nitroprusside; antifungals; angiotensin II receptor antagonist; antiepileptics; β-blockers; antibacterials. Alcohol.
Mechanism of Action: Etizolam is a derivative of benzodiazepine that is used for the short-term treatment of insomnia and anxiety disorder. It has the same general properties with that of diazepam.
MIMS Class
Hypnotics & Sedatives
Disclaimer: This information is independently developed by MIMS based on Etizolam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in